Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-HDS vs R-CHOP in High-Risk DLBCL
NCT00355199Phase 3Completed
- Sponsor
- GITIL
- Start
- May 2005
- Primary completion
- Mar 2013
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab, cyclophosphamide, cytarabine, methotrexate, etoposide in diffuse large B-cell lymphoma (DLBCL), sponsored by GITIL. Started May 2005; status: completed.
02
Drugs
rituximabcyclophosphamidecytarabinemethotrexateetoposide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00355199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00355199.